Delta-Fly Pharmaの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2020/06/08 | 2,287 | 2,344 | 2,260 | 2,314 | +33 | +1.4% | 290,800 |
2020/06/05 | 2,207 | 2,288 | 2,185 | 2,281 | +29 | +1.3% | 370,800 |
2020/06/04 | 2,258 | 2,405 | 2,232 | 2,252 | -84 | -3.6% | 1,026,600 |
2020/06/03 | 2,215 | 2,479 | 2,111 | 2,336 | +75 | +3.3% | 2,047,500 |
2020/06/02 | 2,171 | 2,261 | 2,090 | 2,261 | +400 | +21.5% | 1,176,100 |
2020/06/01 | 1,826 | 1,936 | 1,782 | 1,861 | +103 | +5.9% | 530,300 |
2020/05/29 | 1,663 | 1,795 | 1,658 | 1,758 | +84 | +5% | 397,600 |
2020/05/28 | 1,625 | 1,680 | 1,557 | 1,674 | +25 | +1.5% | 272,800 |
2020/05/27 | 1,650 | 1,697 | 1,620 | 1,649 | -27 | -1.6% | 304,900 |
2020/05/26 | 1,720 | 1,823 | 1,580 | 1,676 | +36 | +2.2% | 901,300 |
2020/05/25 | 1,610 | 1,669 | 1,600 | 1,640 | +134 | +8.9% | 392,500 |
2020/05/22 | 1,507 | 1,569 | 1,473 | 1,506 | -14 | -0.9% | 224,100 |
2020/05/21 | 1,545 | 1,583 | 1,506 | 1,520 | -33 | -2.1% | 230,800 |
2020/05/20 | 1,563 | 1,614 | 1,546 | 1,553 | -9 | -0.6% | 163,700 |
2020/05/19 | 1,600 | 1,608 | 1,520 | 1,562 | -18 | -1.1% | 205,300 |
2020/05/18 | 1,519 | 1,626 | 1,515 | 1,580 | +91 | +6.1% | 418,700 |
2020/05/15 | 1,411 | 1,530 | 1,400 | 1,489 | +99 | +7.1% | 416,500 |
2020/05/14 | 1,421 | 1,469 | 1,378 | 1,390 | -53 | -3.7% | 188,000 |
2020/05/13 | 1,425 | 1,520 | 1,411 | 1,443 | +38 | +2.7% | 357,100 |
2020/05/12 | 1,407 | 1,450 | 1,392 | 1,405 | -5 | -0.4% | 145,800 |
2020/05/11 | 1,397 | 1,479 | 1,385 | 1,410 | +20 | +1.4% | 172,500 |
2020/05/08 | 1,550 | 1,568 | 1,370 | 1,390 | -90 | -6.1% | 467,000 |
2020/05/07 | 1,461 | 1,514 | 1,401 | 1,480 | +1 | +0.1% | 250,300 |
2020/05/01 | 1,472 | 1,569 | 1,436 | 1,479 | -16 | -1.1% | 382,900 |
2020/04/30 | 1,590 | 1,621 | 1,456 | 1,495 | -103 | -6.4% | 515,000 |
2020/04/28 | 1,688 | 1,689 | 1,543 | 1,598 | -82 | -4.9% | 365,200 |
2020/04/27 | 1,688 | 1,870 | 1,615 | 1,680 | -17 | -1% | 974,700 |
2020/04/24 | 1,850 | 2,138 | 1,646 | 1,697 | -93 | -5.2% | 2,908,800 |
2020/04/23 | 1,580 | 1,790 | 1,462 | 1,790 | +300 | +20.1% | 511,800 |
2020/04/22 | 1,625 | 1,665 | 1,451 | 1,490 | -255 | -14.6% | 484,200 |
2020/04/21 | 1,745 | 1,745 | 1,745 | 1,745 | +300 | +20.8% | 25,000 |
2020/04/20 | 1,190 | 1,445 | 1,074 | 1,445 | +300 | +26.2% | 201,300 |
2020/04/17 | 1,111 | 1,145 | 1,104 | 1,145 | +150 | +15.1% | 43,800 |
2020/04/16 | 977 | 1,024 | 968 | 995 | +19 | +1.9% | 57,000 |
2020/04/15 | 900 | 1,022 | 896 | 976 | +71 | +7.8% | 110,100 |
2020/04/14 | 875 | 933 | 875 | 905 | +34 | +3.9% | 57,700 |
2020/04/13 | 870 | 914 | 850 | 871 | +13 | +1.5% | 48,000 |
2020/04/10 | 885 | 885 | 846 | 858 | -22 | -2.5% | 23,900 |
2020/04/09 | 819 | 890 | 800 | 880 | +68 | +8.4% | 54,200 |
2020/04/08 | 792 | 813 | 759 | 812 | +32 | +4.1% | 22,600 |
2020/04/07 | 760 | 810 | 755 | 780 | +50 | +6.8% | 43,600 |
2020/04/06 | 726 | 742 | 690 | 730 | +27 | +3.8% | 38,700 |
2020/04/03 | 758 | 760 | 688 | 703 | -40 | -5.4% | 50,000 |
2020/04/02 | 750 | 769 | 731 | 743 | -15 | -2% | 29,700 |
2020/04/01 | 771 | 800 | 740 | 758 | -23 | -2.9% | 34,800 |
2020/03/31 | 795 | 840 | 777 | 781 | +37 | +5% | 72,000 |
2020/03/30 | 739 | 783 | 733 | 744 | -2 | -0.3% | 46,200 |
2020/03/27 | 785 | 797 | 741 | 746 | -14 | -1.8% | 51,900 |
2020/03/26 | 830 | 850 | 758 | 760 | -125 | -14.1% | 79,100 |
2020/03/25 | 920 | 920 | 850 | 885 | +41 | +4.9% | 56,600 |
1201~
1250
件表示中 / 1598件
類似銘柄と比較する
現在ご覧いただいている「DELTA-P」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
DELTA-P | 45,600円 | - | - | 0.00% | - | 14.13倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
カルナバイオ | 28,000円 | +13.5% | - | 0.00% | - | 2.16倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
DWTI | 10,200円 | -15.1% | - | 0.00% | - | 6.31倍 |
|
三重大学発創薬ベンチャー。プロテインキナーゼ阻害剤開発技術はじめ眼病治療薬開発に集中 |
免疫生物 | 47,400円 | +13.4% | +44.0% | 0.00% | 20.54倍 | 3.30倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
VIS | 67,300円 | +306.2% | - | 0.00% | 25.98倍 | 1.98倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム